Atypical lymphoplasmacytic and immunoblastic proliferation: A Systematic Review

• Published in: Journal of Clinical and Experimental Hematopathology Vol. 64; no. 2; pp. 97 - 106
• Main Authors: Nishimura, Midori Filiz, Takahashi, Toshiaki, Takaoka, Kensuke, Macapagal, Sharina, Wannaphut, Chalothorn, Nishikori, Asami, Toda, Hiroko, Nishimura, Yoshito, Sato, Yasuharu
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society for Lymphoreticular Tissue Research 01-01-2024; JSLRT
• Subjects: angioimmunoblastic T-cell lymphoma; atypical lymphoplasmacytic and immunoblastic proliferation; Autoimmune Diseases - diagnosis; Autoimmune Diseases - pathology; Female; Humans; IgG4-related disease; Lymph Nodes - pathology; Lymphadenopathy - diagnosis; Lymphadenopathy - pathology; Lymphoproliferative Disorders - diagnosis; Lymphoproliferative Disorders - pathology; Male; Middle Aged; Original; systematic review; atypical lymphoplasmacytic and immunoblastic proliferation; angioimmunoblastic T-cell lymphoma; IgG4-related disease; systematic review
• ISSN: 1346-4280; 1880-9952
• DOI: 10.3960/jslrt.24007

Atypical lymphoplasmacytic and immunoblastic proliferation (ALPIBP) was first reported in 1984 as characteristic histological findings in lymph nodes associated with autoimmune diseases, but it has not been clearly defined to date. To summarize the histological characteristics and clinical diagnoses associated with ALPIBP, we searched MEDLINE and EMBASE for all peer-reviewed articles using keywords including “atypical lymphoplasmacytic and immunoblastic lymphadenopathy” from their inception to December 27, 2023. We also summarized the courses of three cases with a pathological diagnosis of ALPIBP. Nine articles with 52 cases were included. Among the total of 55 cases, including the three from our institution, the median age of the cases was 63.5 years with a female predominance (69.5%). Lymphadenopathy was generalized in 65.6% and regional in 34.4% of cases. RA (24.4%), SLE (24.4%), and autoimmune hemolytic anemia (20.0%), were common clinical diagnoses. A combination of cytotoxic chemotherapy was used in 15.6% of cases due to the suspicion of malignancy. Nodal T-follicular helper cell lymphoma, angioimmunoblastic type, methotrexate-associated lymphoproliferative disorders, and IgG4-related diseases were listed as important diseases that need to be pathologically differentiated from ALPIBP. This review summarizes the current understanding of the characteristics of ALPIBP. Given that underrecognition of ALPIBP could lead to overdiagnosis of hematological malignancy and unnecessary treatment, increased awareness of the condition in pathologists and clinicians is crucial.